Austin, Texas-based Apollo focuses on less-invasive therapies for the treatment of obesity and gastrointestinal disorders. Its investors include affiliates of PTV Healthcare Capital, H.I.G. BioHealth Partners, Remeditex Ventures, Novo A/S and CPMG Inc. Apollo’s deal to merge with San Diego, Calif.-based Lpath, which develops lipidomic-based therapeutic antibodies, was first announced Sept.